Cell Line Development Global Market Report 2024 by The Business Research Company | Thermo Fisher Scientific Inc., Novartis AG, Danaher Corporation, Merck KGaA, GE Health Care, AGC Biologics, Corning Inc., Eurofins Scientific, Lonza Pvt. Ltd., WuXi App tec

The cell line development market size has grown rapidly in recent years. It will grow from $7.16 billion in 2023 to $8.21 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increased vaccine production, increased aging population, and increased clinical trails.

The cell line development market size is expected to see rapid growth in the next few years. It will grow to $14.25 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing prevalence of chronic diseases, incresing government investments in healthcare. Major trends in the forecast period include partnerships, investments, and product innovations.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15536&type=smp

Cell Line Development Market Major Segments
The cell line development market covered in this report is segmented -

1) By Product : Reagents And Media, Equipment , Accessories And Consumables
2) By Source: Mammalian, Non-Mammalian
3) By Cell Line: Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line
4) By Application: Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research

Key Driver - Rising Colorectal Cancer Incidence Fuels Growth In The Ostomy Device Market

An increase in increasing prevalence of cancer is expected to propel the growth of cell line development going forward. Cancer is a term used to describe a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The cancer has been rising with pre dominant factors related to population growth and aging, lifestyle choices, obesity, and genetical factor. Cell lines provide a platform for screening potential drug for their efficacy in treating chronic diseases. Researchers are exposed to various compounds and observe its effects, helping them to identify promising drug compound for further development. For instance, in February 2024, according to the World Health Organization, a Switzerland-based government organization, over 35 million new cancer cases are expected by 2050, a 77% surge from the estimated 20 million cases in 2022. Therefore, an increasing prevalence of cancer drives the cell line development market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15536&type=smp

Prominent Trend - Innovative Platforms Drive Competition In The Cell Line Development Market

Major companies operating in the cell line development market are developing innovative platforms to gain a competitive edge in the market. The innovative cell line development platforms stand out for their ability to streamline and optimize the cell line development process, offering speed, efficiency, enhanced productivity to support the development of biological drug. For instance, in January 2023, Abzena, a UK-based that provides outsourced research, development, and manufacturing services launched new platforms called AbZelect and AbZelectPro aimed at accelerating the cell line development (CLD) process for biologic drug programs. These platforms offer higher productivity, enabling the production of more drug substances per manufacturing run. This increased efficiency not only expands capacity and reduces costs for customers but also speeds up the delivery of critical therapies to patients in need.

Cell Line Development Market Players
Major companies operating in the cell line development market are Thermo Fisher Scientific Inc., Novartis AG, Danaher Corporation, Merck KGaA, GE Health Care, AGC Biologics, Corning Inc., Eurofins Scientific, Lonza Pvt. Ltd., WuXi App tech, Sartorius AG, GenScript Biotech Corporation, FUJIFILM Diosynth Biotechnologies, Promega corporation, KBI Biopharma Inc., Rentschler Biopharma SE, Advanced Instruments LLC, Cyagen, Horizon Discovery Group Plc, Probiogen AG, PromoCell GmbH, Premas Biotech, Imgenex, NAEJA RGM Pharmaceuticals Inc

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/cell-line-development-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the cell line development market in 2023. The regions covered in the cell line development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Cell Line Development Market Report Structure
3. Cell Line Development Market Trends And Strategies
4. Cell Line Development Market - Macro Economic Scenario
5. Cell Line Development Market Size And Growth
…..
27. Cell Line Development Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.